Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 13/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20928145 | 0.88 | KIT (0.51) | KITRETAURKAAURKBINCENP | |
| SCHEMBL22568674 | 0.88 | KIT (0.45) | KITAURKAAURKBINCENPTPX2 | |
| SCHEMBL20920004 | 0.86 | KIT (0.60) | KITRETLRRK2 | |
| SCHEMBL22568711 | 0.84 | IDE (0.52) | KITAURKAAURKBINCENPTPX2 | |
| SCHEMBL20927963 | 0.84 | KIT (0.46) | KITAURKAAURKBINCENPTPX2 | |
| SCHEMBL22568644 | 0.84 | KIT (0.46) | KITAURKAAURKBINCENPTPX2 | |
| SCHEMBL22568642 | 0.83 | KIT (0.51) | KITAURKAAURKBINCENPTPX2 | |
| SCHEMBL20928384 | 0.82 | KIT (0.50) | KITAURKAAURKBINCENPTPX2 | |
| SCHEMBL20928276 | 0.82 | TBK1 (0.51) | KITTBK1 | |
| SCHEMBL22568780 | 0.82 | KIT (0.47) | KITAURKAAURKBINCENPTPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200331908-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2020-10-22 | — | — | US | disclosed |
| WO-2019079649-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | ALK, ACVR1, ACVR2A | KIT 318/4885RET 46/4885AURKA 144/4885 |
| US-20200331908-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ALK, ACVR1, ACVR2A | KIT 318/4885RET 46/4885AURKA 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.